<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04030780</url>
  </required_header>
  <id_info>
    <org_study_id>S62043</org_study_id>
    <nct_id>NCT04030780</nct_id>
  </id_info>
  <brief_title>Effect of Sporebiotics in FD</brief_title>
  <official_title>Effect of Spore-forming Probiotics in Functional Dyspepsia Patients: a Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MY HEALTH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-site prospective interventional study aiming to demonstrate the effect of&#xD;
      spore-forming probiotics on dyspeptic symptoms and blood, saliva and stool parameters in FD&#xD;
      patients with and without acid suppression, compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized placebo-controlled study in 2 parallel FD cohorts (8 weeks) with&#xD;
      open-label extension phase (8 weeks):&#xD;
&#xD;
        -  cohort 1FD (on-PPI): study procedures at inclusion (1) and after 8 weeks on-PPI+&#xD;
           sporebiotics or placebo (2) followed by 8 weeks on-PPI+ sporebiotics (open label)&#xD;
&#xD;
        -  cohort 2FD (off-PPI): study procedures at inclusion (1) and after 8 weeks of&#xD;
           sporebiotics or placebo (2) followed by 8 weeks of sporebiotics (open label)&#xD;
&#xD;
      Clinical outcomes and blood, saliva and stool parameters will be assessed at the beginning&#xD;
      and end of each treatment period (week 0, 8 and 16) with additional questionnaires after 1&#xD;
      month (week 4 and 12).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized placebo-controlled study in 2 parallel FD cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>participants, care providers, investigators and outcomes assessor are blinded during the randomized placebo-controlled phase (8 weeks) but not during the open-label extension phase (8 weeks)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of clinical responders (first 8 weeks) in sporebiotics vs. placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Leuven Postprandial Distress Scale (LPDS) is a daily diary assessing the severity of 11 upper gastrointestinal symptoms scored from 0 (none) to 4 (very severe). A difference of 0.7 from baseline for the cardinal PDS symptoms (average of first 3 questions) will be used as a cut-off to determine clinical response by comparing averaged pre-treatment scores with the average score during the last week on treatment with sporebiotics vs. placebo. Only subjects with baseline score &gt;1 (mild) will be included in the intention-to-treat and per-protocol analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of minimal clinical responders (first 8 weeks) in sporebiotics vs. placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Leuven Postprandial Distress Scale (LPDS) is a daily diary assessing the severity of 11 upper gastrointestinal symptoms scored from 0 (none) to 4 (very severe). Proportion of minimal clinical responders using the minimum clinically important difference (MCID) of 0.5 for the cardinal PDS symptoms (first 3 questions) in subjects with baseline score &gt;1 (mild) will be compared between sporebiotics and placebo for both cohorts combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly PDS symptoms from baseline (first 8 weeks) on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Leuven Postprandial Distress Scale (LPDS) is a daily diary assessing the severity of 11 upper gastrointestinal symptoms scored from 0 (none) to 4 (very severe). Change in weekly PDS symptoms (first 3 questions) will be compared within- and between-treatments for both cohorts combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly EPS symptoms from baseline (first 8 weeks) on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Leuven Postprandial Distress Scale (LPDS) is a daily diary assessing the severity of 11 upper gastrointestinal symptoms scored from 0 (none) to 4 (very severe). Change in weekly EPS symptoms (questions 4+5) will be compared within- and between-treatments for both cohorts combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly individual symptoms from baseline (first 8 weeks) on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Leuven Postprandial Distress Scale (LPDS) is a daily diary assessing the severity of 11 upper gastrointestinal symptoms scored from 0 (none) to 4 (very severe). Change in weekly individual symptoms will be compared within- and between-treatments for both cohorts combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of (minimal) clinical responders (3 of the last 4 weeks of treatment) in sporebiotics vs. placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of (minimal) clinical responders for the cardinal PDS symptoms (first 3 questions) in subjects with baseline score &gt;1 (mild) will be compared for 3 of the last 4 weeks of treatment between sporebiotics and placebo for both cohorts combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly (minimal) clinical responder rates in sporebiotics vs. placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in weekly proportions for the cardinal PDS symptoms (first 3 questions) in subjects with baseline score &gt;1 (mild) will be compared within- and between-treatments for both cohorts combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in monthly PAGI-SYM score from baseline (first 8 weeks) on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Patient Assessment of GastroIntestinal SYMptom severity (PAGI-SYM) is a validated questionnaire assessing the severity of 20 symptoms scored from 0 (none) to 4 (very severe). Change in monthly scores will be compared within- and between-treatments for both cohorts combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in monthly PAGI-QOL score from baseline (first 8 weeks) on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Patient Assessment of GastroIntestinal Quality Of Life (PAGI-QOL) is a validated questionnaire assessing 30 items scored from 0 (all the time) to 5 (none of the time). Change in monthly scores will be compared within- and between-treatments for both cohorts combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high-sensitivity C-reactive protein (hs-CRP) on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in hs-CRP (mg/L) sporebiotics vs. placebo and within-group by comparing pre- with post-treatment values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral blood mononuclear cells on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in proportion of PBMC (measured by flow-cytometry) on sporebiotics vs. placebo and changes within-groups by comparing pre- with post-treatment values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma cytokines on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in cytokines (measured by multiplex) on sporebiotics vs. placebo and changes within-groups by comparing pre- with post-treatment values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipopolysaccharide-binding protein (LBP) on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in LBP (ng/mL) on sporebiotics vs. placebo and changes within-groups by comparing pre- with post-treatment values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stool microbiota on sporebiotics vs. placebo and changes within-groups</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in stool microbiota (quantitative microbiota profiles) on sporebiotics vs. placebo and changes within-groups by comparing pre- with post-treatment values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of sporebiotics vs. placebo</measure>
    <time_frame>16 weeks</time_frame>
    <description>number of adverse events with sporebiotics vs. placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Dysbiosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1FD (on-PPI+sporebiotics)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study procedures at inclusion (1) and after 8 weeks on-PPI+ sporebiotics (2) followed by 8 weeks on-PPI+ sporebiotics (open label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1FD (on-PPI+placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>study procedures at inclusion (1) and after 8 weeks on-PPI+ placebo (2) followed by 8 weeks on-PPI+ sporebiotics (open label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2FD (off-PPI+sporebiotics)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study procedures at inclusion (1) and after 8 weeks of sporebiotics (2) followed by 8 weeks of sporebiotics (open label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2FD (off-PPI+placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>study procedures at inclusion (1) and after 8 weeks of placebo (2) followed by 8 weeks of sporebiotics (open label)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>spore-forming probiotic</intervention_name>
    <description>spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks</description>
    <arm_group_label>Cohort 1FD (on-PPI+sporebiotics)</arm_group_label>
    <arm_group_label>Cohort 2FD (off-PPI+sporebiotics)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>similar capsules administered twice daily</description>
    <arm_group_label>Cohort 1FD (on-PPI+placebo)</arm_group_label>
    <arm_group_label>Cohort 2FD (off-PPI+placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;18 years with FD diagnosis (Rome IV criteria)&#xD;
&#xD;
          -  Male or female (not pregnant or lactating and using contraception or postmenopausal)&#xD;
&#xD;
          -  Normal bowel habits (defecation once every 3 days up to 3 times a day)&#xD;
&#xD;
          -  Witnessed written informed consent&#xD;
&#xD;
          -  Access to home freezer (-18 to -20Â°C)&#xD;
&#xD;
          -  Capable to understand and comply with the study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active somatic or psychiatric condition that may explain dyspeptic symptoms&#xD;
             (stable dose of single antidepressant allowed for psychiatric indication, no&#xD;
             limitation for other indications)&#xD;
&#xD;
          -  Predominant symptoms of gastro-esophageal reflux disease (GERD) or irritable bowel&#xD;
             syndrome (IBS)&#xD;
&#xD;
          -  Use of immunosuppressants or antibiotics &lt;3 months&#xD;
&#xD;
          -  History of major abdominal surgery (except for appendectomy, cholecystectomy or&#xD;
             splenectomy)&#xD;
&#xD;
          -  Personal history of diabetes mellitus type 1, celiac disease or inflammatory bowel&#xD;
             disease&#xD;
&#xD;
          -  Diabetes mellitus type 2 (including therapy)&#xD;
&#xD;
          -  Active malignancy (including therapy)&#xD;
&#xD;
          -  Known HIV, HBV or HCV infection (including therapy)&#xD;
&#xD;
          -  Significant alcohol use (&gt;10 units/weeks)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Vanuytsel, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spore-forming probiotic</keyword>
  <keyword>sporebiotic</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

